DefenCath works with the most commonly used HD‑CVCs
and features: ready to use 3mL single-use vials, refrigeration-free storage and seamless workflow integration
DefenCath is administered similarly to standard-of-care (heparin).1,2
Available in single-dose 3 mL vials1
DefenCath is available as a sterile, preservative-free, clear, aqueous-based solution that consists of taurolidine 40.5 mg/3 mL (13.5 mg/mL) and heparin 3,000 USP Units/3 mL (1,000 USP Units/mL).
Not actual size.
Administration is similar to current CLS practices
Important reminders while administering:
- DefenCath is for instillation in CVCs only1
- DefenCath is not intended for systemic administration1
- Do not use DefenCath as a catheter lock flush product1
- DefenCath must be aspirated from the catheter and discarded prior to the initiation of the next HD session1
Preparing for administration
Before accessing the catheter, follow the CDC's for preparing the catheter hubs prior to catheter access.
The following steps outline the administration process from syringes:
Withdraw a sufficient volume of DefenCath from the vial using a sterile needle and syringe to fill the catheter lumens1
Slowly instill DefenCath into each catheter lumen1
Discard any unused portion of DefenCath remaining in the vial.1
Please see full Prescribing Information for complete instructions.
How DefenCath®
(taurolidine and heparin) catheter lock solution is supplied and stored
Single-dose vials1
- DefenCath is available in 3 mL vials and is supplied in cartons containing 10 vials.
- Each vial contains a sterile, preservative-free, clear aqueous-based solution for instillation in central venous catheters.
Storage requirements1
- DefenCath vials must be stored at a controlled room temperature of 20°C to 25°C (68°F to 77°F).
- Do not freeze.
- Vials must be stored in the commercial carton, prior to the instillation in CVCs.
Please see full Prescribing Information for complete instructions.
Speak with a representative
Have questions about DefenCath? Open the form below to request a call with a representative.
Open formIMPORTANT SAFETY INFORMATION (cont'd)
CONTRAINDICATIONS
DefenCath is contraindicated in patients with:
- Known heparin-induced thrombocytopenia (HIT).
- Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DefenCath), or pork products.
WARNINGS AND PRECAUTIONS
- Heparin-Induced Thrombocytopenia (HIT): HIT was reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If HIT occurs, discontinue DefenCath and institute appropriate supportive measures.
- Drug Hypersensitivity: Drug hypersensitivity reactions have been reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If a hypersensitivity reaction occurs, discontinue DefenCath and institute appropriate supportive measures.
ADVERSE REACTIONS
The most frequently reported adverse reactions occurring in ≥2% of patients using DefenCath as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.
Indications and Usage
LIMITED POPULATION: DefenCath® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
Limitations of Use
The safety and effectiveness of DefenCath have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.
Please see the full Prescribing Information.